Early Cardiac Testing after Emergency-Department ECG: An Observational Target-Trial Emulation

In emergency rooms around the world, doctors face a constant, high-stakes puzzle: determining which patients with chest pain are having a heart attack and which are not. To solve this, they rely on tools like electrocardiograms, which record the heart's electrical activity, and blood tests that detect specific proteins released when heart muscle is damaged. Based on these initial clues, clinicians decide whether a patient needs further, more invasive testing, such as a stress test or a catheterization procedure to look inside the arteries. This decision-making process is not random; doctors naturally choose to test patients who appear sicker or more dangerous. This creates a tricky situation for researchers trying to understand the true value of these tests. If you simply compare the health outcomes of patients who were tested against those who were not, the results will be misleading. The tested group will look worse, not because the tests harmed them, but because they were already the sickest people in the room to begin with. This phenomenon, where the reason for a treatment is mixed up with the treatment itself, makes it incredibly difficult to tell if a medical intervention is actually helping or hurting.

To cut through this confusion, a researcher named Bjørn-Jostein Singstad conducted a study that reimagined how we look at real-world medical data. Instead of trying to prove that cardiac testing causes better or worse outcomes, the study asked a more specific question: if we could magically compare patients who received testing within ten days of an emergency visit against those who did not, while carefully accounting for how sick they were at the start, what would the difference in their health be? The researcher used a method called target-trial emulation, which is a way of designing an observational study to mimic the structure of a perfect, randomized experiment. By linking data from over 71,000 emergency room visits at a major hospital between 2010 and 2015, the study focused on 51,158 encounters where patients had both an electrocardiogram and linked medical records. The goal was to measure the risk of a bad outcome—defined as either a positive heart protein test or death within thirty days—comparing those who underwent stress tests or catheterizations within ten days against those who did not.

The initial look at the data showed a stark and expected difference. Patients who received cardiac testing had a much higher rate of bad outcomes, with nearly 29 percent experiencing a positive test or death, compared to only 7 percent of those who were not tested. This gap of 22 percentage points is exactly what one would expect when sicker patients are selectively chosen for testing. However, the study went much deeper than this surface-level comparison. Using advanced statistical techniques that act like a sophisticated filter, the researcher adjusted for dozens of factors, including age, gender, race, and the specific patterns seen on the patients' initial electrocardiograms. These adjustments were designed to level the playing field, creating a fair comparison between the two groups as if they had started with the same level of risk.

After applying these adjustments, the massive gap in outcomes shrank dramatically. The difference in risk dropped from 22 percentage points down to roughly 6 percentage points. This means that even after accounting for the fact that the tested patients were sicker, there was still a small, positive difference in risk favoring the untested group, suggesting that the testing strategy itself might be associated with slightly worse outcomes. However, the study did not stop there, because the researcher knew that the way the data was organized could still hide hidden problems. One major issue is something called "immortal time bias," which occurs when the definition of a group requires a patient to survive long enough to be classified into it. In this study, a patient had to stay in the hospital or survive for up to ten days to be counted as "tested." If a patient died on day two, they could not be in the tested group, making the tested group look artificially healthier in the early days.

To test how much this timing issue mattered, the researcher changed the rules of the game. When the window for defining "testing" was shortened from ten days to just one day, the estimated difference in risk collapsed almost entirely to zero. This suggests that the small risk difference seen in the ten-day window might not be a true effect of the testing, but rather an artifact of how the groups were defined over time. Furthermore, the study examined a specific piece of information: whether a patient had been diagnosed with a heart attack on the same day as their visit. This diagnosis appeared in 43 percent of the tested patients but in zero percent of the untested patients. When the researcher removed this specific piece of information from the analysis, the estimated risk difference nearly doubled, jumping from about 6 percentage points to 11 percentage points. This finding highlights how fragile the results can be when dealing with data where the timing of a diagnosis and the decision to test are so closely intertwined.

The study also calculated a value to measure how strong an unmeasured factor would need to be to completely explain away the results. The number came out to 2.66, which implies that if there were a hidden factor, such as the severity of a patient's symptoms that doctors could not record, that was more than twice as likely to cause both testing and bad outcomes, it could erase the small difference found in the analysis. Given that doctors make testing decisions based on subtle clinical cues that are often not captured in databases, such a hidden factor is entirely plausible. The researcher concluded that while the statistical methods successfully reduced the obvious bias caused by selecting sicker patients for testing, they could not eliminate the uncertainty caused by missing information and the complex timing of real-world medical decisions.

Ultimately, this work serves as a powerful demonstration of the limits of observational data. It shows that even with the most sophisticated mathematical tools and the best available records, we cannot fully replicate the certainty of a controlled experiment when the data comes from the messy reality of emergency medicine. The study did not prove that cardiac testing is harmful, nor did it prove it is useless. Instead, it revealed that the small differences seen in the data are highly sensitive to how the question is asked and which pieces of information are included. The lesson is one of caution: while modern methods can help us see through the fog of confounding, they cannot clear away the shadows of unrecorded clinical judgment or the intricate timing of life-and-death decisions. The results suggest that the apparent link between testing and poor outcomes is likely a reflection of the patients' underlying severity and the complexities of the data, rather than a simple cause-and-effect relationship that can be easily fixed by adjusting a few numbers.